This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
© 2019 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Join our 1,253 Daily Subscribers And Get This FREE Commentary In Your E-Mail!
MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN SHARES OF TSLA, GOOGL, AAPL
Good Morning Today is Monday, January 7
- S&P 500 futures are pointing to a lower opening of 2 points as of 7:50 AM
- The US 10-year rate is at 2.64%
- Dollar Index is at 95.94
- WTI Crude Oil is $49.14
- VIX: 22.92
- Critical events for today: Eli Lilly to buy Loxo Oncology for $8 billion, China and US resume trade talks, ISM Services Index estimates of 58.4
Recap of International Trading:
- Hong Kong Hang Seng Index up 0.82%
- Japan up 2.44%
- China Shanghai Comp. up 0.72%
- UK FTSE down 0.48%
- Dax down 0.47%
S&P 500 (SPY)
Stocks are flat on the day but there is plenty of bullish news around today especially out of biotech was the JP Morgan Health Care conference kick’s – off.
Biotech stocks are getting a lift on some positive headlines. The XBI ETF is likely to rise to around $79.
Eli Lilly/ Loxo
Eli Lilly is buying Loxo Oncology for $8 billion or $235 per share. Loxo had been trading at $139.87 on Friday. The shares are trading higher to $221
Pivotal Research upgraded Alphabet to buy from hold and placed a $1240 price target on the stock. A rise above $1,100 would trigger a breakout and a potential move to $1,175
Pivotal also initiated coverage of Amazon with a $1920 price target. For now, resistance remains around $1620.
Pivotal also upgrade Salesforce to buy with a $164 price target. Resistance comes around $149.
Tesla broke ground in China to build its Giga factory and expects to start Model 3 production later this year. The stocks next level of resistance will come around $340.
Apple will now offer iTunes Movies and shows on Samsung tvs. Apple has room to fill the gap at around $157.
Exact Sciences is surging premarket after pre-announcing its fourth quarter guidance, raising revenue guidance to $143 million at the mid-point from $127.4 million. Should the stock increases above $68.25 it has room to go higher to around $70.
Sage Therapeutics (SAGE)
Sage is jumping by 33% today after the company reported positive data on its drug SAGE-217 in female patients with severe postpartum depression. $140 is resistance for the stock.
Micron Upgraded to Outperform from Market Perform at BMO. $34 is the next immediate level of resistance.
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.